Macro Focus
Futures for the Dow Jones Industrial Average climbed 91 points to 18,623.00, while the Standard & Poor’s 500 index futures
gained 9 points to 2,169.25. Futures for the Nasdaq 100 index surged 30.50 points to 4,851.00.
Oil prices traded lower as Brent crude futures fell 0.19 percent to trade at $46.27 per barrel, while US WTI crude futures also
fell 0.91 percent to trade at $44.86 a barrel.
Initial Jobless Claims for Nov 4 254.0K vs 260.0K estimate. Prior reading was 265.0K. Continuing Claims for Oct 28 2.04M vs
2.03M estimate.
- St. Louis Federal Reserve Bank President James Bullard is set to speak in St. Louis, Mo. at 9:15 a.m. ET.
- The Energy Information Administration’s weekly report on natural gas stocks is schedule for release at 10:30 a.m. ET.
- The Treasury budget data for October is schedule for release at 2:00 p.m. ET.
- Data on money supply for the recent week will be released at 4:30 p.m. ET.
BZ News Desk Focus
-
Macy's (NYSE: M) Reports Q3 Adj. EPS $0.17,
Sales $5.63B vs $5.65B Est.
-
Kohl's (NYSE: KSS) Reports Q3 Adj. EPS
$0.80 vs $0.70 Est., Sales $4.327B vs $4.33B Est.
-
Taser (NASDAQ: TASR) Reports Q3 EPS
$0.07 vs. Est. $0.06, Sales $71.9M vs $59M Est.
-
Mylan (NASDAQ: MYL) Reports Q3 EPS $1.38
vs. Est. $1.46, Rev. $3.06B vs. Est. $3.12B
-
Shake Shack (NYSE: SHAK) Reports Q3 Adj
EPS $0.15 vs $0.14 Est, Revenue $74.6M vs $69.33M, Comps Up $2.9%
Sell-Side Themes
Barclays upgraded a few defensive names. Lockheed Martin (NYSE: LMT) got an Equal-Weight rating and $275 target, while Northrup
Grumman (NYSE: NOC) got bumped to Overweight with a
$270 target. L-3 Communications (NYSE: L) was
upgraded to Overweight with a $165 target.
Sell-Side's Most Noteworthy Calls
- Rodman & Renshaw downgraded Valeant (NYSE:
VRX) to Neutral.
- Morgan Stanely downgraded Qualcomm (NASDAQ: QCOM) to Equal-Weight.
- Bank of America upgraded IBM (NYSE: IBM)
to Buy.
- JPMorgan upgraded Humana (NYSE: HUM) to
Overweight.
- Goldman Sachs started Cal-Maine Foods (NASDAQ: CALM) at Neutral.
Deal Talk
Merrimack Pharmaceuticals (NASDAQ: MACK)
is said to be working with Credit Suisse and Bank of America on a strategic review that could lead to a sale of assets or a
licensing deal, according to sources as reported by Reuters on Wednesday. AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) might have an interest in the company's cancer drugs, the sources said.
Investors in MDC Partners (NASDAQ: MDCA)
are breathing a
sigh of relief following news the company reached an agreement in principle to settle a probe with the SEC. Albert Fried's Rich
Tullo has urged the company to merge with a big player like Publicis. He sees the timeline for such a deal before the second
quarter of 2017.
Ron Burkle and Sam Nazarian’s SBE Entertainment were close to seeing the window close on their ability to
complete their buyout of the Morgans Hotel Group. Morgans is running out of cash and needs to find a buyer/financing by year
end.
In The News
Over the last couple of weeks, Carl Icahn has taken “buying the dip” to the extreme. With that idea in mind and his most recent
13F filing as a guide, traders can look for other Icahn favorites that he could be looking
to buy next.
Donald Trump’s stunning presidential victory shook the political establishment to its core and sent shock waves through global
markets. Wall Street Journal broke it down
hour-by-hour.
Blogosphere
This Reddit
thread is freaking out about the Trump win: "Seriously guys, buy now for stupidly cheap and wait for the markets to eventually
rise. Don't sell, that's stupid you'll lose all potential profit."
Trending
HIMX KSS TASR M KORS TRIP CXW SODA PRGO AEG
Thousands acorss the country protsted in major scities following DOnald Trump's Presdiential eclection win. #TrumpProtest
- This company reported on Thursday Q3 Adj. EPS $0.80 vs $0.70 Est., Sales $4.327B vs $4.33B Est. Also comps were down 1.7% in
Q3.
- In July, this company was rumored to have obtained financing for a "going private" deal, at the same time they cancelled out
of a conference.
- Sympathy plays include Sears, JC Penney and Macy's
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.